ArticleDrugs - real world outcomes2026
The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUp to half of cancer patients treated with immune checkpoint inhibitors (ICIs) develop immune-related adverse events (irAEs). However, the long-term consequences of irAEs remain poorly characterized.
objectiveThis study investigated the likelihood of chronic irAEs, challenges related to their corticosteroid treatment and clinical workload associated with their management.
methodsWe retrospectively analyzed 230 patients who received ICIs at Kuopio University Hospital, Finland, between the years 2015 and 2024.
resultsIrAEs were chronic in 60.9% of patients who developed toxicities. Thyroiditis was the most common chronic AE (40%). Of the patients with irAE+, 42.9% were treated with systemic corticosteroids and steroid-related AEs were observed in 58% of them. Corticosteroid usage for ≥ 3 months was associated with an increased risk of steroid-related AEs (< 3 months 38.2% vs ≥ 3 months 78.8%, p < 0.001). An average of 5.3 contacts with a medical oncologist was needed for the management of an irAE, with the highest workload associated with hepatitis (10.0 contacts/irAE) and colitis (6.1 contacts/irAE).
conclusionsThe characterization of the long-term sequelae of irAEs and the associated clinical workload is crucial for proper patient education and clinical resource planning.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.